How Long Does Oxycodone Stay in Your System?

Oxycodone stays in your system for 24 hours to 90 days, depending on the type of test used. Blood tests detect oxycodone for about 24 hours, urine tests for 3 to 4 days, saliva tests for up to 4 days, and hair follicle tests for as long as 90 days. Understanding oxycodone detection windows matters whether you are managing a prescription, preparing for a drug screen, or questioning whether oxycodone use has become opioid use disorder (OUD).

Key Takeaways

• Oxycodone has an average half-life of 3.2 to 4 hours for immediate-release formulations, meaning the drug is largely cleared from blood within 24 hours, but its metabolites remain detectable far longer depending on the test type used.
• New Jersey recorded 2,816 overdose deaths in 2023, the majority involving opioids, according to the New Jersey State Unintentional Drug Overdose Reporting System (SUDORS) and the New Jersey Department of Health (NJDOH). Opioid misuse, including misuse of prescription painkillers like oxycodone, remains a leading driver of these deaths.
• Urine testing is the most widely used method for oxycodone detection, capturing use within a 1 to 4 day window; hair follicle testing extends that window to 90 days.
• Liver function, kidney health, frequency of use, and genetic differences in CYP3A4 and CYP2D6 enzyme activity are the primary factors that determine how quickly oxycodone clears any individual’s system.
• Oxycodone use disorder is treatable. Evidence-based therapies including Cognitive Behavioral Therapy (CBT) and Dialectical Behavior Therapy (DBT), combined with medications like buprenorphine and naltrexone, significantly reduce cravings and relapse risk.

What Is Oxycodone and How Does the Body Process It?

Oxycodone is a Schedule II semi-synthetic opioid analgesic that binds directly to mu-opioid receptors in the brain and spinal cord, producing pain relief and euphoria. It is available in immediate-release formulations (brand names Roxicodone, Percocet) and extended-release formulations (OxyContin), and is prescribed primarily for moderate to severe pain where other treatments are inadequate.

How the Liver Breaks Down Oxycodone

When oxycodone enters the body, the liver processes it through the cytochrome P450 enzyme system. Approximately 45 to 50 percent of each dose is converted by the CYP3A4 enzyme into noroxycodone, a largely inactive metabolite. A secondary pathway, driven by the CYP2D6 enzyme, converts roughly 10 to 19 percent of the dose into oxymorphone, an active metabolite that binds to mu-opioid receptors with three to five times greater affinity than oxycodone itself. These metabolites then undergo glucuronide conjugation before being excreted by the kidneys through urine.

Half-Life and Clearance

Immediate-release oxycodone carries an average elimination half-life of approximately 3.2 to 4 hours. It takes five half-lives for a drug to clear the bloodstream, placing full blood clearance for immediate-release oxycodone at roughly 20 to 24 hours after the last dose. Extended-release oxycodone is engineered to release the drug gradually over 12 hours, producing a longer half-life of approximately 4.5 to 5.6 hours and extending blood clearance to around 28 to 32 hours. Oxymorphone and noroxycodone carry longer biological half-lives than the parent drug, which is why urine and hair tests remain positive well after oxycodone’s pain-relieving effects have worn off.

What Factors Affect How Long Oxycodone Stays in Your System?

Several biological and behavioral factors control how quickly or slowly oxycodone and its metabolites leave the body. These factors explain why two people taking the same dose can have very different detection windows.

Liver and Kidney Function

The liver performs the primary metabolic breakdown of oxycodone via the CYP3A4 and CYP2D6 enzyme pathways, while the kidneys clear the resulting metabolites through urine. Liver disease or impairment reduces CYP enzyme activity, slowing metabolism and extending the time oxycodone stays in the system. Kidney impairment reduces the clearance rate of noroxycodone and other glucuronide conjugates, causing these metabolites to accumulate and remain detectable longer.

Genetic Enzyme Differences

Genetic polymorphisms in the CYP2D6 gene create meaningful differences in how fast people metabolize oxycodone. Individuals classified as poor metabolizers by CYP2D6 genotype convert significantly less oxycodone to oxymorphone, producing lower active metabolite levels but potentially slower overall clearance. Ultra-rapid metabolizers convert oxycodone to oxymorphone at much higher rates, increasing the drug’s potency and altering its detection profile. These inherited enzyme differences directly affect both clinical response and the duration that oxycodone metabolites remain detectable in biological samples.

Dose and Frequency of Use

Higher doses and repeated use allow oxycodone and its metabolites to accumulate in fatty tissue and plasma. A single low dose of immediate-release oxycodone (5 mg) clears urine in approximately 2 to 3 days, while chronic high-dose use can extend urinary detection to 4 days or longer. Extended-release formulations remain detectable for longer than immediate-release equivalents because the drug is still being absorbed and processed while earlier doses are still metabolizing.

Age, Body Composition, and Hydration

Older adults tend to have reduced liver enzyme activity and lower kidney clearance rates, extending oxycodone detection windows compared to younger adults. Higher body fat percentage allows oxycodone to sequester in adipose tissue, releasing slowly back into the bloodstream over time. Dehydration concentrates urine, potentially raising metabolite levels above detection thresholds for longer periods than in a well-hydrated individual.

Drug Interactions

Medications that inhibit CYP3A4 activity, including certain antifungal agents such as ketoconazole and some antibiotics, block the primary oxycodone clearance pathway. This inhibition triples oxymorphone exposure while reducing noroxycodone levels, effectively concentrating the active drug and its metabolites in the system for longer. Medications that induce CYP3A4, such as rifampin and carbamazepine, accelerate oxycodone metabolism and shorten detection windows.

Oxycodone Detection Windows by Test Type

Each drug test uses a different biological sample with a different detection window. The table below summarizes the standard detection windows for oxycodone across all four major test types.

Test Type	Detection Window	Onset of Detectability	Common Use
Urine	1 to 4 days	1 to 3 hours after use	Employment, probation, treatment
Blood	Up to 24 hours	15 to 30 minutes after use	Medical or emergency settings
Saliva	1 to 4 days	Within 15 to 30 minutes	Roadside testing, workplace screening
Hair Follicle	Up to 90 days	5 to 7 days after use	Legal, forensic, long-term use assessment

1. Urine Test

Urine testing is the most widely used method for oxycodone detection in employment, addiction treatment, and criminal justice contexts. Oxycodone becomes detectable in urine within 1 to 3 hours of ingestion as the kidneys begin excreting oxymorphone and noroxycodone glucuronide conjugates. Detection windows run 1 to 4 days for standard single or occasional use, extending beyond 4 days for chronic heavy use. Labs measure metabolite concentration in nanograms per milliliter (ng/mL), with standard cutoff thresholds set at 300 ng/mL.

2. Blood Test

Blood tests detect the parent oxycodone molecule rather than metabolites, and produce the shortest detection window of any test type. Oxycodone appears in blood within 15 to 30 minutes of ingestion and remains detectable for up to 24 hours. Because oxycodone clears the bloodstream before its metabolites clear urine, blood tests are typically reserved for medical emergencies, suspected overdose assessments, or situations where very recent use needs to be confirmed. Blood testing is more invasive and costly than urine testing and is rarely used for routine drug screening.

3. Saliva Test

Saliva testing detects oxycodone metabolites in oral fluid within 15 to 30 minutes of use and maintains a detection window of 1 to 4 days. Saliva tests are non-invasive, difficult to tamper with, and increasingly used for roadside law enforcement testing and workplace screenings where immediate results are needed. Heavy or chronic use may extend saliva detection beyond 4 days, though this is uncommon in single-dose scenarios.

4. Hair Follicle Test

Hair follicle tests provide the longest detection window because oxycodone metabolites are deposited into the hair shaft as it grows from the follicle. At a standard growth rate of approximately 0.5 inches per month, a 1.5-inch hair sample captures approximately 90 days of drug use history. Hair follicle testing does not detect very recent use, as metabolites typically require 5 to 7 days to appear in the hair shaft. This test is used in legal proceedings, forensic investigations, and long-term use assessments rather than for routine screening.

Signs of Oxycodone Dependence and Withdrawal

Oxycodone binds repeatedly to mu-opioid receptors in the nucleus accumbens and the ventral tegmental area, driving dopamine release and progressively downregulating the brain’s natural opioid receptor density. This neuroadaptation produces physical dependence, where the absence of oxycodone triggers a withdrawal syndrome measurable on the Clinical Opiate Withdrawal Scale (COWS), an 11-item clinician-administered instrument that rates withdrawal severity from 0 to 48. COWS scores of 5 to 12 indicate mild withdrawal, 13 to 24 indicate moderate, 25 to 36 indicate moderately severe, and scores above 36 indicate severe withdrawal requiring immediate clinical intervention.

Common Signs of Oxycodone Dependence

Oxycodone dependence often develops before the person experiencing it recognizes it as a problem. The following patterns signal physical and psychological dependence on oxycodone:

• Tolerance buildup: Needing higher doses to achieve the same pain relief or euphoric effect that lower doses previously produced, driven by mu-opioid receptor downregulation.
• Clock-watching and dose-timing: Feeling anxious, restless, or uncomfortable between doses, a reliable sign that the brain now depends on oxycodone to maintain baseline function.
• Continued use despite consequences: Persisting with oxycodone even after it causes job loss, relationship damage, or health complications, a key diagnostic criterion for opioid use disorder under DSM-5-TR.
• Unsuccessful attempts to cut down: Repeatedly trying and failing to reduce or stop oxycodone use is one of the 11 DSM-5-TR criteria for opioid use disorder and signals the need for structured treatment support.
• Preoccupation with obtaining oxycodone: Spending significant time thinking about, obtaining, or recovering from oxycodone use, including seeking multiple prescriptions or obtaining the drug through non-prescribed channels.

Oxycodone Withdrawal Symptoms

Oxycodone withdrawal begins 8 to 12 hours after the last dose for immediate-release formulations, as the mu-opioid receptors that have been chronically suppressed rebound without the drug present. The following symptoms characterize the oxycodone withdrawal syndrome:

• Early phase (8 to 24 hours): Anxiety, restlessness, insomnia, yawning, runny nose, sweating, and muscle aches begin as central nervous system norepinephrine pathways rebound from opioid-mediated suppression.
• Peak phase (24 to 72 hours): Nausea, vomiting, diarrhea, abdominal cramping, elevated pulse and blood pressure, dilated pupils, and intense opioid cravings mark the peak withdrawal period and carry the highest risk of relapse.
• Subacute phase (days 4 to 10): Physical symptoms begin resolving, but insomnia, depression, fatigue, and dysphoria often persist as the brain’s dopaminergic reward circuitry slowly recalibrates.
• Protracted withdrawal: Some individuals experience persistent low-grade symptoms, including anxiety, sleep disruption, and opioid cravings, for weeks to months after the acute phase resolves, a phenomenon called protracted opioid abstinence syndrome driven by lasting changes in the mesolimbic dopamine system.

When to Seek Help

Oxycodone withdrawal carries serious medical risks, particularly the risk of dehydration from severe vomiting and diarrhea, cardiovascular stress from elevated blood pressure and heart rate, and relapse to a higher dose after a period of abstinence has lowered opioid tolerance. Medical supervision during oxycodone withdrawal significantly reduces these risks. Seek immediate evaluation if withdrawal symptoms include chest pain, confusion, seizures, or severe dehydration that prevents fluid intake. Anyone who has unsuccessfully attempted to stop oxycodone without help should contact a drug withdrawal treatment program before attempting another unsupervised taper.

Oxycodone vs. OxyContin: What Is the Difference?

Oxycodone and OxyContin both contain oxycodone hydrochloride as the active molecule, but they differ fundamentally in how and how quickly that molecule is released into the body.

Feature	Oxycodone (Immediate-Release)	OxyContin (Extended-Release)
Brand names	Roxicodone, Percocet (with acetaminophen)	OxyContin
Release mechanism	Full dose released immediately	Dose released gradually over 12 hours
Half-life	~3.2 to 4 hours	~4.5 to 5.6 hours
Dosing frequency	Every 4 to 6 hours as needed	Every 12 hours
Blood clearance	~20 to 24 hours	~28 to 32 hours
Urine detection	1 to 4 days	Up to 4 days (longer in heavy use)
Misuse risk	High: rapid onset produces intense euphoria	High: abuse-deterrent reformulation introduced in 2010

The abuse-deterrent reformulation of OxyContin introduced in 2010 made the tablet gel-like when crushed or dissolved, reducing intravenous and intranasal misuse. Both formulations carry equivalent opioid use disorder risk when used at high doses or outside prescribed guidelines. Drug tests do not distinguish between immediate-release oxycodone and OxyContin. Both produce the same metabolite signature in urine, saliva, blood, and hair.

Treatment for Oxycodone Use Disorder

Oxycodone use disorder responds well to evidence-based treatment combining behavioral therapies and pharmacological support. Right Choice Recovery, a Joint Commission-accredited outpatient center in Dayton, New Jersey, provides individualized care across multiple levels of integration, integrating CBT, DBT, motivational interviewing, mindfulness, and holistic therapies like Reiki and yoga. The clinical team, led by Christina Wittkop, MS, LCADC, and Rachele McGowan, accepts Tricare and VACCN in-network and works with out-of-network benefits. Treatment should begin early after recognition of dependence, as early intervention produces significantly better long-term outcomes.

First-Line Behavioral Therapies

Behavioral therapies form the foundation of oxycodone use disorder treatment by targeting the cognitive and emotional mechanisms that drive continued opioid use:

• Cognitive Behavioral Therapy (CBT): CBT identifies and restructures the distorted thought patterns and maladaptive coping strategies that maintain opioid use, replacing them with evidence-based problem-solving and relapse prevention skills. Research consistently demonstrates CBT reduces opioid relapse rates when delivered in both individual and group formats.
• Dialectical Behavior Therapy (DBT): DBT addresses the emotional dysregulation that frequently drives opioid misuse, teaching distress tolerance, mindfulness, and interpersonal effectiveness skills that reduce the need for substances as emotional coping tools.
• Motivational Interviewing (MI): MI strengthens the person’s internal motivation for change by resolving ambivalence about treatment and building self-efficacy for sustained recovery, making it particularly effective in early treatment engagement.

First-Line Pharmacological Treatments

Medications for opioid use disorder (MOUD) are FDA-approved treatments that significantly reduce cravings, prevent withdrawal, and lower overdose mortality. Buprenorphine (brand: Suboxone when combined with naloxone) is a partial mu-opioid agonist that blunts withdrawal symptoms and cravings without producing the full euphoric response of oxycodone. Methadone is a full mu-opioid agonist dispensed through federally licensed opioid treatment programs (OTPs), providing stable receptor occupancy that prevents withdrawal and blocks the euphoric effects of illicitly used opioids. Naltrexone (brand: Vivitrol) is a mu-opioid receptor antagonist that completely blocks opioid effects, making it most effective after full detoxification when used in combination with behavioral therapy. The medication-assisted treatment (MAT) page covers the evidence base for each medication in detail.

Second-Line and Adjunct Treatments

Relapse prevention therapy (RPT) provides structured coping strategies specifically targeting opioid-related triggers, high-risk situations, and the cognitive distortions that precede relapse. Group therapy formats, including 12-step facilitation and SMART Recovery, provide social accountability and peer modeling that individual therapy alone cannot replicate. Trauma-focused therapies including Eye Movement Desensitization and Reprocessing (EMDR) and somatic experiencing address underlying adverse childhood experiences (ACEs) and post-traumatic stress disorder (PTSD) that function as primary drivers of opioid use disorder in a significant portion of the treatment-seeking population. The trauma therapy page provides an overview of how trauma-focused approaches are integrated into substance use disorder treatment.

Emerging and Investigational Treatments

Low-dose naltrexone (LDN) is being investigated in Phase 2 clinical trials as an adjunct to standard MOUD protocols for reducing protracted opioid abstinence syndrome symptoms, including persistent dysphoria and insomnia. Transcranial magnetic stimulation (TMS), currently FDA-cleared for treatment-resistant depression, is in Phase 3 trials for opioid use disorder, targeting the dorsolateral prefrontal cortex to restore inhibitory control over drug-seeking behavior. Mindfulness-based relapse prevention (MBRP), combining mindfulness meditation with cognitive relapse prevention strategies, has shown statistically significant reductions in opioid craving intensity in recent randomized controlled trials and is increasingly integrated into evidence-based outpatient programs.

References

1. Lalovic, B., Kharasch, E., Hoffer, C., Risler, L., Liu-Chen, L. Y., & Shen, D. D. (2006). Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clinical Pharmacology & Therapeutics, 79(5), 461–479.
2. National Center for Biotechnology Information. (2024). Oxycodone. In StatPearls. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK482226/
3. Huddart, R., Fohner, A. E., Whirl-Carrillo, M., Hoffman, J. M., Cavallari, L. H., Relling, M. V., & Klein, T. E. (2019). PharmGKB summary: oxycodone pathway, pharmacokinetics. Pharmacogenetics and Genomics, 29(9), 230–237. PMC6602093.
4. New Jersey Department of Health. (2025, March 26). Statewide overdose deaths decline across all racial and ethnic groups as NJ Health Department authorizes harm reduction centers in all counties. NJDOH. https://www.nj.gov/health/news/2025/approved/20250326a.shtml
5. Wesson, D. R., & Ling, W. (2003). The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs, 35(2), 253–259.
6. Substance Abuse and Mental Health Services Administration. (2023). Medications for opioid use disorder: Treatment improvement protocol (TIP) 63. SAMHSA.
7. American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). APA. (Opioid use disorder criteria, pp. 645–655.)
8. Tompkins, D. A., Bigelow, G. E., Harrison, J. A., Johnson, R. E., Fudala, P. J., & Strain, E. C. (2009). Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug and Alcohol Dependence, 105(1–2), 154–159.